About Avalon Ventures
Avalon Ventures is a venture capital firm founded in 1983. It is primarily based out of Cambridge, United States. As of Apr 2024, Avalon Ventures has invested in 100 companies. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Enterprise Applications to Life Sciences and Enterprise Infrastructure. Most recently it participated in the $***** Series A round of Enlaza Overall, Avalon Ventures portfolio has seen 8 IPOs and 48 acquisitions including key companies like Zynga, Kaltura and Syndax. A lot of funds co-invest with Avalon Ventures, with names like GSK sharing a substantial percentage of its portfolio. Avalon Ventures has team of 6 people including 4 partners.Key Metrics
Team Members
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Seed & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Avalon Ventures' List of Top Investments
Avalon Ventures has a portfolio of 100 companies. Their most notable investments are in ScoreStream and Backupify.Their portfolio spans across United States, Belgium and United Kingdom. They have invested in Enterprise Applications, Life Sciences, Enterprise Infrastructure and 16 other sectors, across stages such as Series A, Seed and 4 more. Here is the list of top investments by Avalon Ventures:1. Zynga
Casual games developer and publisher for mobile and web platforms. The games developed by the company inlcude High heels, Cashier 3D, Blob runner 3D, and many more. The games are available for iOS and Android users.
Key facts about Zynga
- Founded Year: 2007
- Location: San Francisco (United States)
- Annual Revenue: $1B+ as on Dec 31, 2021
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $526M
- Employee Count: 2,892 as on Jun 30, 2026
- Investors: Sprout Capital Partners, Adams Street Partners and 38 Others
- Latest Funding Round: Post IPO, Dec 15, 2020, $*****
- Highlight: Acquired
2. Kaltura
Provider of video solutions for webinars, events, hubs, and virtual classrooms. The company delivers tools for corporate communication, higher education, marketing, sales, employee training, media, and telecom sectors. It offers an AI video suite, webinars, video portal, events management, and virtual classroom platforms. The company provides solutions for content repurposing, knowledge management, and audience engagement.
Key facts about Kaltura
- Founded Year: 2006
- Location: New York City (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $145M
- Employee Count: 727 as on Jun 30, 2026
- Investors: Sapphire Ventures, Luminari Capital and 16 Others
- Latest Funding Round: Series D, Aug 08, 2016, $*****
- Highlight: Public
3. Syndax
Developer of targeted therapies for the treatment of cancer. The company is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma and triple negative breast cancer.
Key facts about Syndax
- Founded Year: 2005
- Location: Waltham (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $198M
- Employee Count: 336 as on Jun 30, 2026
- Investors: Boxer Capital, ArrowMark Partners and 19 Others
- Latest Funding Round: Post IPO, Jan 31, 2020, $*****
- Highlight: Public
4. Primer
Primer develops a text analytics solution that uses a combination of supervised and unsupervised machine learning models to ingest large quantities of textual data and provide summaries of what it deems the most important information. It uses 6 computational engines to help it summarize and contextualize data. Primer claims that its platform is used by government agencies and Fortune 50 companies.
Key facts about Primer
- Founded Year: 2015
- Location: San Francisco (United States)
- Stage: Series D
- Total Funding till date: $237M
- Employee Count: 118 as on Jun 30, 2026
- Investors: AME Cloud Ventures, Mubadala and 19 Others
- Latest Funding Round: Series D, Jun 14, 2023, $*****
- Highlight: Editors' Pick
5. Neurocrine
Developer of small molecule therapeutics for endocrine and CNS disorders. The company's product line include elagolix, a gonadotropin-releasing hormone antagonist for endometriosis and uterine leiomyoma, and NBI-98854 a vesicular monoamine transporter 2 inhibitor for the treatment of movement disorders.
Key facts about Neurocrine
- Founded Year: 1992
- Location: San Diego (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $10M
- Employee Count: 2,402 as on Jun 30, 2026
- Investors: BB Biotech, Avalon Ventures and 5 Others
- Latest Funding Round: Post IPO, Aug 05, 2023, $*****
- Highlight: Acquired
Avalon Ventures' Year-on-Year Investment Trends
Avalon Ventures has invested in 100 companies over the last 33 years, with an average of 1 new investment annually in the last 10 years. Its most recent first time investment was in Enlaza and most recent follow-on round was in Enlaza.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 0 | 0 | 0 |
2025 | 0 | 0 | 0 |
2024 | 0 | 1 | 1 |
2023 | 0 | 0 | 0 |
2022 | 2 | 1 | 3 |
2021 | 2 | 3 | 5 |
2020 | 0 | 2 | 2 |
2019 | 0 | 1 | 1 |
2018 | 2 | 4 | 6 |
2017 | 4 | 4 | 8 |
Avalon Ventures' Investments by Stage
Avalon Ventures is primarily an Early Stage Investor investor majorly investing in Series A (45) rounds where average round size is $437M, Seed (12) rounds where average round size is $83.7M and Series B (12) rounds where average round size is $212M.Stage of entry | No. of Investments |
|---|---|
Series A | 45 |
Seed | 12 |
Series B | 12 |
Series D | 3 |
Series C | 2 |
Others | 1 |
Note: We have considered here, only first round of investments
Avalon Ventures' Investments by Sector
Avalon Ventures has a diverse portfolio, with companies operating in the Enterprise Applications, Life Sciences, Enterprise Infrastructure, High Tech and FinTech. Notably, it has invested in 81 Tech companies, 64 Enterprise (B2B) companies, 53 Software companies and at least 26 companies focusing on Saas.Sector | No. of Investments |
|---|---|
Enterprise Applications | 35 |
Life Sciences | 20 |
Enterprise Infrastructure | 15 |
High Tech | 8 |
FinTech | 7 |
Others | 38 |
Note: We have considered here, only first round of investments
Avalon Ventures' Investments by Geography
Avalon Ventures has made most investments in United States (73), followed by Belgium where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 73 |
Belgium | 1 |
United Kingdom | 1 |
Note: We have considered here, only first round of investments
Avalon Ventures' recent investments
Avalon Ventures has not made any investment in 2026 so far.Here are the most recent investments by Avalon Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Apr 30, 2024 | United States | Series A | 4891 | [+8] | |
Dec 15, 2022 | United States | Seed | 9393 | ||
Nov 02, 2022 | United States | Series C | 1967 | ||
Mar 04, 2022 | United States | Series B | 5981 | [+6] | |
Sep 01, 2021 | United States | Series A | 1889 |
IPOs and Publicly Listed companies in Avalon Ventures' Portfolio
8 of Avalon Ventures' portfolio companies have become public. Kaltura got listed on the New York Stock Exchange (NYSE), in Jul 2021 at marketcap of $1.24B and Janux Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $678M.Here are Avalon Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 21, 2021 | 2007 | Series A | 8298 | |
Jun 11, 2021 | Mar 03, 2021 | Series A | 7322 | |
Mar 26, 2021 | - | - | 5708 | |
Jan 17, 2017 | Nov 08, 2007 | Series B | 8491 | |
Mar 03, 2016 | Apr 03, 2007 | Series A | 8973 |
Acquired companies in Avalon Ventures' Portfolio
48 companies from Avalon Ventures' portfolio have been acquired. The most recent acquisition was Skycatch in Jul 2026 by Caterpillar for $*****.Here are Avalon Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Jul 07, 2026 | May 22, 2014 | Series A | 6803 | |
Jan 08, 2026 | - | - | 9198 | |
Dec 10, 2024 | Feb 2008 | Series A | 4632 | |
Dec 11, 2023 | Aug 18, 2014 | Series A | 8766 | |
Jul 19, 2023 | Feb 12, 2016 | Seed | 9462 |
Team profile of Avalon Ventures
Avalon Ventures has a team of 6 members including 4 Partners and 1 Principal located in United States. Avalon Ventures' team sits on the board of 1 company.Here is a list of all team members in Avalon Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Diego | - | ||
Partner | Belmont | - | ||
Partner | Boston | - | ||
Partner | Rancho Santa Fe | |||
Principal | Meridian | - | - |
Co-investors of Avalon Ventures
Over the past 33 years, 355 investors have co-invested in Avalon Ventures's portfolio companies. This includes funds and angels.
- Invested before Avalon Ventures: Y Combinator, Lerer Hippeau and 57 others have invested in rounds before Avalon Ventures. There are 6 companies where Y Combinator has invested before Avalon Ventures and 3 companies where Lerer Hippeau has invested before Avalon Ventures.
- Top Co-investors of Avalon Ventures: 117 investors entered a company along with Avalon Ventures. These include investors like GSK (5 companies).
- Invested after Avalon Ventures: A total of 179 investors have invested in Avalon Ventures's portfolio after their investments. Top Investors include Intel Capital (4 companies), SVB (3 companies) and Orbimed (3 companies).
Recent News related to Avalon Ventures
•
•
Enlaza Therapeutics Secures $100 Million Series A Financingfromgeek.com•May 28, 2024•Enlaza, JPMorgan Chase, Amgen, Regeneron Pharmaceuticals and 4 others
•
Enlaza Therapeutics Raises $100M in Series A FinancingFinSMEs•Apr 30, 2024•Frazier Life Sciences, Enlaza, Avalon Ventures, Lightspeed Venture Partners and 7 others
•
•
Avalon Ventures spins off a separate fund to handle life science companiesEndPoints News•Dec 06, 2022•Avalon Ventures
•
•
Roche doubles down on Jnana’s RAPID platform in $2B dealMed Ad News•Nov 15, 2022•Roche, Jnana Therapeutics, Bain Capital, RA Capital Management and 4 others
•
Joy Raises $20 Million For Its Free All-In-One Wedding Planning PlatformForbes•Sep 01, 2021•Joy, Valor Equity Partners, Zola Global, Avalon Ventures and 2 others
•
•
Janux Therapeutics’ $125 Million Series B FinancingGlobal Legal Chronicle•May 01, 2021•Janux Therapeutics, Wilson Sonsini Goodrich & Rosati, RA Capital Management, EcoR1 and 9 others
